Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics. Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology.
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
August 11, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022